Osiris Therapeutics, a publicly traded Maryland biotechnology company, won a $224.7 million contract from the Department of Defense to develop Prochymal, a drug that will treat military personnel exposed to radiation from nuclear or radiological attacks.  For more on this story, visit U.S. Deal Boosts Radiation Drug and return to comment below.